ATLANTA, Feb. 28, 2025 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) today reported results for the fourth quarter and full year ended December 31, 2024. Results shown are from continuing operations. When referring to any comparative period, all metrics are pro forma for continuing operations of the combined business of Chart and Howden (pro forma excludes the following businesses that were divested in 2023: Roots™, American Fan, Cofimco and Cryo Diffusion). The Howden acquisition closed on March 17, 2023. Fourth quarter 2024 highlights compared to fourth quarter 2023, pro forma:Orders of $1.55 billion, increased 29.4% and included phase one Woodside Louisiana LNG order Sales of $1.11 billion, increased 10.8% excluding foreign exchange (“FX”) Reported operating income of $188.3 million (17.0% of sales) or $243.4...

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous malformations Advanced three new clinical studies across oncology, rare disease, and recurrent C. diff infection with REC-1245, REC-4881, and REC-3964 Delivered milestones for partners including the first neuro-phenomap for Roche and Genentech and two milestones for Sanofi for aggregate cash inflows of $45 million Completed business combination with Exscientia, cementing a position as a leading TechBio companySALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its...

Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023. Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023. Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023. Announces global Distribution and Collaboration Agreement with MilliporeSigmaLEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions...

Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8% Total Rare Disease quarterly net revenue of $87.0 million, which includes:Record quarterly net revenue for Purified Cortrophin® Gel of $59.4 million, an increase of 42.3% year-over-year, and ILUVIEN® and YUTIQ® net revenues of $27.6 million in the first full quarter of ownership following the acquisition of Alimera SciencesDelivered record quarterly adjusted non-GAAP EBITDA of $50.0 million, an increase of 65.7% year-over-year Diluted GAAP loss per share of $(0.55) and adjusted non-GAAP diluted earnings per share of $1.63 Increased 2025 guidance with expected net revenues of $756.0 million to $776.0 million and adjusted non-GAAP EBITDA of $190.0 million to $200.0 million; announced adjusted non-GAAP diluted earnings per share guidance...

Castellum, Inc. Announces 2024 Unaudited Financial ResultsCastellum, Inc. (NYSE-American: CTM) (“Castellum” or “the Company”) announces certain unaudited highlights of its operating results for its year ended December 31, 2024 – www.castellumus.comVIENNA, Va., Feb. 28, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum” or “the Company”), a cybersecurity, electronic warfare, and software services company focused on the federal government, announces certain unaudited highlights of its operating results for its year ended December 31, 2024. Revenue for 2024 was $44.8 million, down slightly from $45.2 million in 2023. Operating loss was ($7.2 million) versus ($16.7 million) in 2023, which included $6.9 million of non-cash charges for goodwill impairment. Management uses a Non-GAAP measure, Adjusted...

09:30 London 11:30 Helsinki   28 February 2025 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL STATEMENTS RELEASE 2024    H2/24 H2/23 FY2024 FY2023Revenue EUR million 57.2 58.3 128.6 153.7EBITDA EUR million -1.6 1.5 2.6 16.6EBIT EUR million -3.2 0.6 -0.1 15.0Earnings before taxes EUR million -7.2 -0.2 -5.3 12.0Loss for the period EUR million -7.8 -0.5 -7.2 10.0Earnings per share EUR -0.03 0.00 -0.03 0.04EBITDA margin % -2.9 2.5 2.0 10.8EBIT margin % -5.6 1.2 -0.1 9.8Earnings margin % -12.5 -0.3 -4.1 7.8Personnel (end of period)   602 595 602 595SECOND HALF 2024 HIGHLIGHTSRevenue for the second half of 2024 decreased to EUR 57.2 (H2/2023: 58.3) million; Speciality Alloys processed material sold increased by 25.2%, to 9,837 (H2/2023: 7,854)...

ZETADISPLAY AB (publ) Year end Report 1 October – 31 December 2024 (Q4) Q4 Interim report for ZetaDisplay AB (publ) is now available at ir.zetadisplay.comReport summaryOCTOBER – DECEMBER 2024 • Adjusted recurring revenue* increased by 16.8% to SEK 65.8 (56.3) million • Recurring revenue increased by 9.7 % to 65.8 (60.0) million • Adjusted net sales* increased by 15.2% to SEK 172.8 (150.0) million • Net sales increased by 5.1 % to SEK 169.6 (161.4) million • Adjusted gross margin* increased to 55.4% (43.5%) • Gross margin increased to 53.4% (50.8%) • Adjusted EBITDA* increased to SEK 26.9 (15.0) millionCEO commentGROWTH, SCALE BENEFITS, AND STRATEGIC WINS STRENGTHEN ZETADISPLAY FOR THE FUTURE Net sales for the quarter increased to SEK 172.8 (150.0) million, with recurring revenue rising by 16.8% to SEK 65.8 (56.3) million, representing...

Innofactor Plc Financial Statements Bulletin February 28, 2025, at 9:00 a.m. Finnish time Key figures of the group, IFRS. Jul 1–Dec 31, 2024 Jul 1–Dec 31, 2023 Change   Jan 1–Dec 31, 2024 Jan 1–Dec 31, 2023 ChangeNet sales, EUR thousand 36,525 39,945 -8.6%   77,576 80,263 -3.3%Growth of net sales -8.6% 0.9%     -3.3% 12.8%  Operating result before depreciation and amortization (EBITDA), EUR thousand 3,134 4,849 -35.4%   6,338 9,101 -30.4%percentage of net sales 8.6% 12.1%     8.2% 11.3%  Operating profit/loss (EBIT), EUR thousand 1,693 3,140 -46.1%   3,386 5,835 -42.0%percentage of net sales 4.6% 7.9%     4.4% 7.3%  Earnings before taxes, EUR thousand 1,399 3,051 -58.4%   2,940 5,174 -45.7%...

Enefit Green’s consolidated Q4 2024 operating income increased by 5% and operating expenses (excluding depreciation) decreased by 13% compared to the same period last year. Group’s EBITDA increased by 28% to €37.8m and net profit for the period increased by €8.3m to €27.4m. For the full year 2024, group’s operating income decreased by 4%, while operating expenses (excluding depreciation and amortisation) declined by 15% compared to 2023. As a result, the group’s EBITDA improved by 8% to €114.8m and net profit increased by €14.5m to €70.3m. Earnings per share for 2024 grw by 26% to €0.266 (2023: €0.211).Juhan Aguraiuja, Chairman of the Management Board of Enefit Green, comments: “In 2024, we focused on finalizing construction and achieving stable operation of our largest assets. Compared to a year ago, we have grown to become a...

DIGITALIST GROUP’S FINANCIAL STATEMENT RELEASE, 1 JANUARY–31 DECEMBER 2024 (Not audited) DIGITALIST 2024  SUMMARY October–December 2024 (comparable figures for 2023 in parentheses):Turnover: EUR 4.7 million (EUR 4.2 million), change 12.9%.  EBITDA: EUR -0.2 million (EUR -0.4 million*), -4.3% of turnover (-9.1%). EBIT: EUR -0.3 million (EUR -0.6 million*), -7.1% of turnover (-14.4%).  Net income: EUR -1.0 million (EUR -1.6 million*), -21.3% of turnover (-38.9%). Earnings per share EUR -0.00 (EUR -0.00).January–December 2024 (comparable figures for 2023 in parentheses): Turnover: EUR 16.2 million (EUR 16.7 million), change -3.1%.  EBITDA: EUR -1.5 million (EUR -0.9 million**), -9.4% of turnover (-5.2%).  EBIT: EUR -2.0 million (EUR -1.7 million**), -12.3% of turnover (-10.2%).  Net income: EUR -5.0 million (EUR -4.1 million**), -31.0%...